💥 Stay tuned! The era of ISACs (immune stimulatory antibody conjugates) is coming after early setbacks. ⚔️ Incredible talks on next-gen ADCs @sitcancer @BoltBio @OncoAlert ✨#SITC2025

Live from #SITC25: Justin Kenkel, PhD (@BoltBio) presents a novel PD-L1–directed Immune Stimulatory Antibody Conjugate (ISAC) that activates both innate and adaptive immunity to fight cancer. Key takeaways: • Unlike standard PD-L1 blockers, this ISAC delivers a TLR agonist to PD-L1⁺ myeloid cells, activating macrophages and dendritic cells. • Induces cytokine release and repolarizes the tumor microenvironment from immunosuppressive to immune-stimulatory. • Promotes T-cell priming and durable anti-tumor responses in preclinical models. • Offers a promising strategy to overcome resistance to current PD-1/PD-L1 therapies. #MoffittSITC25 @sitcancer

🎉✨ Happy New Year 2025! ✨🎉 2024 has been incredible at Boltzmann Labs! From the launches of #BoltPro & #BoltBio to collaborations with top Institutions & Global showcases, we are redefining #DrugDiscovery with multi-agent AI systems. 🚀🌍 📸 Highlights of our 2024 journey

May is #NationalCancerResearchMonth! At #BoltBio, we’re leveraging the immune system for a better way to treat cancer. We’d like to recognize our #TeamBolt scientists working tirelessly to generate breakthroughs for patients. Learn more: bit.ly/3uV8C3s

Yesterday, #BoltBio Senior Scientist of Analytical Development, Chemistry, Manufacturing & Controls, Halei Zhai, PhD, presented on drug-to-antibody ratio (DAR) distribution during the @World_ADC Analytical Development Summit. Way to go, Halei! #ADCs #TeamBOLT

#BoltBio CEO Randy Schatzman recently spoke with @BioCentury on #ADCs. Our ISAC platform combines immune-stimulants with traditional ADCs for local activation of the #immunesystem to generate a durable tumor-targeted adaptive immune response. Full article: bit.ly/3v6xMfG

Today #BoltBio reported financial results for the fourth quarter full year 2023 and provided corporate updates. Learn more: bit.ly/4a1KQ5j

At #BoltBio, we love pie almost as much as we love science! Our team celebrated #PiDay with a delicious assortment of pies from local businesses. We hope that everyone had an infinitely special π day!

Boltzmann’s AI drug discovery tech stack comprises four more platforms — ReBolt, BoltPro, BoltBio, and ClinBolt. #GenAI #startup (4/4) inc42.com/startups/how-boltz…

#BoltBio Senior Director and Program Team Lead Shelley Ackerman, PhD will present on our Boltbody™ ISAC platform this Wednesday at the @World_ADC London Conference. #WorldADC bit.ly/3uKU3zy

Colorectal Cancer is the third leading cause of cancer-related deaths in the United States. At #BoltBio, we’re developing next-generation therapeutics to generate breakthroughs for patients with #CRC. Learn more: bit.ly/3uV8C3s #CRCAwarenessMonth

Don’t miss #BoltBio CMO @EdithPerezMD at this year’s #IO360° Summit! Dr. Perez is a featured speaker and will discuss TLR targeted stimulation for IO. Learn more: bit.ly/3w4dxiO

#BoltBio management will be in New York for the @GuggenheimPtnrs Healthcare Talks Biotech Conference. We look forward to connecting in person!

We’re just 1 week away from DONNA Marathon Weekend! #BoltBio is hosting this year’s Curb Crew, and encourages spectators to ring their cowbells loudly to support the runners. Learn more about the @DONNAfoundation and their work to FINISH #breastcancer: bit.ly/48PVsUk

We’re headed to San Francisco! Meet with #BoltBio management from Jan 8-10 during #JPMWeek. We look forward to seeing you in person! #JPM2024

2023 was full of achievements at #BoltBio as we progressed our clinical pipeline. Enjoy some of the great moments in our highlights reel and stay tuned for more to come. #Immunooncology #TeamBolt

We’re excited to share that #BoltBio CMO Edith A. Perez, MD recently participated in a panel discussion with @PharmExec on the evolution of Key Opinion Leaders to Digital Opinion Leaders. Read the full article:  bit.ly/3Qgd0So #TeamBolt

Today at #ESMO23, #BoltBio announced updated clinical data from our Phase 1 Dose-Escalation Trial of BDC-1001 for HER2-expressing tumors. Learn more about our findings here: bit.ly/45EPbrX #oncology

#BoltBio will present updated clinical data from our Phase 1 Dose-Escalation Trial of BDC-1001 for HER2 #breastcancer at the #ESMO23 Congress Learn more about the presentations: bit.ly/3RVKirn #oncology

#BoltBio CMO Edith A. Perez, MD will be presenting on the management of #breastcancer at the Association of Hematology and Medical Oncology of Puerto Rico Annual Meeting taking place from October 6-8. Learn more here: ahompr.org/ #AHOMPR #TeamBolt